GlassScriptPhysician profile
Ann G Neff
NPI 1639387095
$2,907.87
in general payments reported to CMS, 2019-2025
20 companies · $866 in 2025
The $866 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $344 · 2020: $177 · 2021: $303 · 2022: $460 · 2023: $454 · 2024: $303 · 2025: $866.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,624.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,623.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $479.90 | 2019-2025 | |
| Janssen Biotech, INC. | $282.85 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Amgen INC. | $223.35 | 2020-2025 | Otezla, Otezla |
| Novartis Pharmaceuticals Corporation | $198.53 | 2020-2022 | |
| Merz North America, INC. | $194.20 | 2019-2025 | |
| Genentech USA, INC. | $187.84 | 2019-2021 | |
| Lilly USA, LLC | $177.58 | 2020-2023 | Taltz |
| Ucb, INC. | $173.56 | 2021-2025 | Bimzelx, Cimzia |
| Biofrontera INC. | $169.54 | 2019-2024 | Xepi, Bf-Rhodoled, Ameluz |
| Regeneron Healthcare Solutions, INC. | $155.04 | 2019-2025 | Dupixent |
| Galderma Laboratories, L.P. | $150.13 | 2024-2025 | Nemluvio, Aklief |
| E.R. Squibb & Sons, L.L.C. | $120.97 | 2022-2024 | Sotyktu |
| Sun Pharmaceutical Industries INC. | $105.63 | 2020-2025 | Blu-U |
| Almirall LLC | $85.51 | 2019-2022 | |
| Janssen Scientific Affairs, LLC | $65.09 | 2025 | Tremfya |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $56.28 | 2023 | Adbry |
| Genzyme Corporation | $33.72 | 2019-2020 | |
| Journey Medical Corporation | $20.00 | 2022 | |
| Incyte Corporation | $14.64 | 2022 | |
| Boston Scientific Corporation | $13.51 | 2025 | General - Therapies |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ann Neff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.